MetaCap

Qiagen N.V. Company Profile

NYSE: QGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

44.53-0.26 (-0.58%)

At close: Oct 8, 4:00 PM ET · Delayed 15 min

Pre-market: 44.84 +0.68%

Qiagen N.V. at a glance

Qiagen N.V. (NYSE: QGEN) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Venlo, Netherlands. Qiagen N.V. is led by Mr. Jonathan M. Pratt and employs about 5,500 people. The company's shares have traded publicly since 2026.

At a market capitalization of $9.23 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001015820, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Qiagen N.V. do?

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Business description based on the company's public filings.

Company information

Legal name
Qiagen N.V.
Ticker
NYSE: QGEN
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Jonathan M. Pratt
Employees
5,500
Headquarters
Hulsterweg 82, Venlo, Netherlands
Phone
31 77 355 6600
Website
qiagen.com
IPO year
2026
SEC CIK
0001015820

Companies similar to Qiagen N.V.

QGEN peer companies
CompanyPrice% ChgMarket capCompare
KYMRKymera Therapeutics Inc.109.30+0.88%$8.99Bvs QGEN
PCVXVaxcyte Inc.65.02-2.90%$9.67Bvs QGEN
KRYSKrystal Biotech Inc.327.30+0.84%$9.69Bvs QGEN
TWSTTwist Bioscience Corporation152.05-2.31%$10.08Bvs QGEN
RGENRepligen Corporation163.84-2.02%$10.40Bvs QGEN
IBRXImmunityBio Inc.9.91+1.64%$10.50Bvs QGEN
TECHBio-Techne Corp72.45-0.11%$11.36Bvs QGEN
IMVTImmunovant Inc.30.26-5.56%$6.25Bvs QGEN

Related